DOP2002000464A - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
DOP2002000464A
DOP2002000464A DO2002000464A DO2002000464A DOP2002000464A DO P2002000464 A DOP2002000464 A DO P2002000464A DO 2002000464 A DO2002000464 A DO 2002000464A DO 2002000464 A DO2002000464 A DO 2002000464A DO P2002000464 A DOP2002000464 A DO P2002000464A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutically acceptable
pyridylquinazoline
dimethoxy
amino
acceptable salt
Prior art date
Application number
DO2002000464A
Other languages
English (en)
Inventor
Michael John Humphrey
John Douglas Davis
Ross James Macras
Janet Sarah Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2002000464A publication Critical patent/DOP2002000464A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una formulación farmacéutica de liberación controlada para administración oral que comprende 4-amino-6, 7-dimetoxi-2- 5-metanosulfonamido- 5 1,2,3,4-tetrahidroisoquinol-2-il -5-2-piridilquinazolina o una sal farmacéuticamente aceptable de la misma; y un adyuvante, diluyente o vehículo farmacéuticamente aceptable; caracterizada porque la formulación está adaptada para liberar al menos un 5O en peso de la 4-amino-6,7-dimetoxi-2-5-me1zanosu1fonamido--1,,3,4-tetrahidro-isoquino1-2-i1-5-2-piridilquinazolina, o la sal farmacéuticamente aceptable de la misma, después de 6 horas en el Aparato 1 descrito en la Farmacopea de Estados Unidos 24 2000, páginas 1941-1943, que tiene recipientes de 1 litro, cestas de malla 40 orificios de 0,4 mm, una velocidad de rotación de 100 rpm y un medio de disolución que consta de 900 ml de ácido clorhídrico 0,01 M que contiene cloruro sódico al 0,7 p/v a 37°C. Las formulaciones de acuerdo con la invención son adecuadas para el tratamiento de la BPH.
DO2002000464A 2001-10-11 2002-09-12 Formulaciones farmaceuticas DOP2002000464A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DOP2002000464A true DOP2002000464A (es) 2003-04-15

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000464A DOP2002000464A (es) 2001-10-11 2002-09-12 Formulaciones farmaceuticas

Country Status (33)

Country Link
EP (1) EP1434570B8 (es)
JP (1) JP4131471B2 (es)
KR (1) KR20050032510A (es)
CN (1) CN1568180A (es)
AP (1) AP2004003001A0 (es)
AR (1) AR036782A1 (es)
AT (1) ATE303135T1 (es)
BR (1) BR0213196A (es)
CA (1) CA2461168A1 (es)
CO (1) CO5560534A2 (es)
DE (1) DE60205925T2 (es)
DK (1) DK1434570T3 (es)
DO (1) DOP2002000464A (es)
EA (1) EA006168B1 (es)
ES (1) ES2246017T3 (es)
GB (1) GB0124455D0 (es)
GT (1) GT200200184A (es)
HR (1) HRP20040261A2 (es)
HU (1) HUP0600064A3 (es)
IL (1) IL160969A0 (es)
IS (1) IS7179A (es)
MA (1) MA27075A1 (es)
MX (1) MXPA04003293A (es)
NO (1) NO20041520L (es)
OA (1) OA12709A (es)
PA (1) PA8556001A1 (es)
PE (1) PE20030551A1 (es)
PL (1) PL369666A1 (es)
PY (1) PY0223360A (es)
SV (1) SV2004001279A (es)
UY (1) UY27477A1 (es)
WO (1) WO2003032956A1 (es)
ZA (1) ZA200401976B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466986B1 (en) * 1990-07-02 1994-04-27 Bend Research, Inc. Asymmetric microporous beads for controlled release
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
WO2001064672A1 (en) * 2000-03-03 2001-09-07 Pfizer Limited 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Also Published As

Publication number Publication date
AP2004003001A0 (en) 2004-03-31
PE20030551A1 (es) 2003-06-26
OA12709A (en) 2006-06-26
EA200400431A1 (ru) 2004-08-26
EA006168B1 (ru) 2005-10-27
ATE303135T1 (de) 2005-09-15
CA2461168A1 (en) 2003-04-24
AR036782A1 (es) 2004-10-06
IS7179A (is) 2004-03-11
NO20041520L (no) 2004-04-05
ES2246017T3 (es) 2006-02-01
HUP0600064A3 (en) 2007-02-28
HUP0600064A2 (en) 2006-06-28
MA27075A1 (fr) 2004-12-20
GT200200184A (es) 2003-05-23
WO2003032956A1 (en) 2003-04-24
HRP20040261A2 (en) 2004-08-31
PL369666A1 (en) 2005-05-02
UY27477A1 (es) 2003-05-30
EP1434570B1 (en) 2005-08-31
MXPA04003293A (es) 2004-07-23
BR0213196A (pt) 2004-08-31
IL160969A0 (en) 2004-08-31
DK1434570T3 (da) 2005-11-07
GB0124455D0 (en) 2001-12-05
JP2005507909A (ja) 2005-03-24
PY0223360A (es) 2004-04-01
KR20050032510A (ko) 2005-04-07
DE60205925T2 (de) 2006-06-08
CO5560534A2 (es) 2005-09-30
ZA200401976B (en) 2004-07-12
EP1434570A1 (en) 2004-07-07
JP4131471B2 (ja) 2008-08-13
EP1434570B8 (en) 2005-10-26
SV2004001279A (es) 2004-02-19
CN1568180A (zh) 2005-01-19
PA8556001A1 (es) 2003-07-28
DE60205925D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
AR035792A1 (es) Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
DK1435909T3 (da) Stabil sammensætning indeholdende partikler i en frossen vandig matrix
WO2005065646A3 (en) Novel drug compositions and dosage forms
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
CO5280073A1 (es) Composiciones
RU2016122609A (ru) Составы соединений азаиндола
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
PE20021017A1 (es) Composicion parenteral reconstituible
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
ATE422356T1 (de) Pharmazeutische zubereitungen
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
MXPA04003293A (es) Formulaciones farmaceuticas.
JP4553569B2 (ja) フェノール系誘導体を有効成分とするクリプトスポリジウム症の予防・治療剤
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
ECSP045045A (es) Formulaciones farmacéuticas de liberación controlada que comprende 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil)quinazolina
JP2005068089A (ja) コロナウイルス消毒剤
SE0002354D0 (sv) New formulation
DK1451184T3 (da) Dimere forbindelser og deres anvendelse som antivirale midler
RU94030464A (ru) Фармацевтическая композиция, способ ее получения, способ лечения заболеваний дыхательных путей, применение фармацевтической композиции